Exercise Capacity Prognostically Beneficial for Patients

This article originally appeared here.
Share this content:
Exercise Capacity Prognostically Beneficial for Patients
Exercise Capacity Prognostically Beneficial for Patients

MONDAY, April 10, 2017 (HealthDay News) -- Cardiopulmonary exercise testing, unless contraindicated, should be performed to obtain an overall view of cardiac and pulmonary patients' clinical status, according to a review published online March 31 in the Annals of the American Thoracic Society.

Stefania Paolillo, M.D., Ph.D., from IRCCS SDN, and Piergiuseppe Agostoni, M.D., Ph.D., from Centro Cardiologico Monzino, both in Italy, address the role of cardiopulmonary exercise for risk stratification in the care of cardiac and pulmonary disorders.

The researchers note that the cardiopulmonary exercise test is a useful prognostic tool for evaluation of several pathological conditions. A cardiopulmonary test should always be performed if not contraindicated; to better stratify patient risk, it should be integrated with clinical, laboratory, and hemodynamic parameters. The cardiopulmonary exercise test is important in all stages of patient management in heart failure, from diagnosis to risk assessment. When included in a multiparametric risk stratification methodology, the prognostic role of cardiopulmonary exercise test in heart failure is amplified. Cardiopulmonary exercise test parameters may help assess the risk of adverse events in respiratory disorders and pulmonary hypertension. The cardiopulmonary exercise test may also help identify the presence of concurrent cardiac and respiratory disorders.

"An integrated multiparametric approach also taking into account cardiopulmonary exercise test variables should always be considered, as long as it is not contraindicated, to stratify the risk of adverse events and to provide measures of survival improvement in these specific populations," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »